Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2011
Clinical use of temporary percutaneous left ventricular assist devices.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Froesch Patric, Martinelli Michele, Meier Pascal, Cook Stéphane, Hullin Roger, Windecker Stephan, Mohacsi Paul, Meier Bernhard
Аннотация
BACKGROUND: Temporary percutaneous left ventricular assist devices (TPLVAD) can be inserted and removed in awake patients. They substitute left ventricular function for a period of up to a few weeks and provide an excellent backup and bridge to recovery or decision.
METHODS: Retrospective analysis of 75 patients who received TPLVAD to treat cardiogenic shock (n = 49) or to facilitate high-risk percutaneous coronary intervention (PCI) (n = 26). Forty-two patients with cardiogenic shock and 16 patients with high-risk PCI received a TandemHeart and 7 patients and 10 patients, respectively, received an Impella Recover LP 2.5. Outcome and related complications up to 1 month are reported with reference to device depending function.
RESULTS: One-month survival was 53% in patients with shock and 96% in patients with PCI.
CONCLUSION: TPLVADs can support the failing heart with acceptable risk. Outcome is better in prophylactic use than in patients with cardiogenic shock.
METHODS: Retrospective analysis of 75 patients who received TPLVAD to treat cardiogenic shock (n = 49) or to facilitate high-risk percutaneous coronary intervention (PCI) (n = 26). Forty-two patients with cardiogenic shock and 16 patients with high-risk PCI received a TandemHeart and 7 patients and 10 patients, respectively, received an Impella Recover LP 2.5. Outcome and related complications up to 1 month are reported with reference to device depending function.
RESULTS: One-month survival was 53% in patients with shock and 96% in patients with PCI.
CONCLUSION: TPLVADs can support the failing heart with acceptable risk. Outcome is better in prophylactic use than in patients with cardiogenic shock.
Предметные рубрики MeSH
AdolescentAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryFemaleHeart-Assist DevicesHospital MortalityHumansMaleMiddle AgedPatient SelectionProsthesis DesignRegistriesRetrospective StudiesRisk AssessmentRisk FactorsShock, CardiogenicSwitzerlandTime FactorsTreatment OutcomeVentricular Function, LeftYoung Adult